Lower limb peripheral arterial disease (referred to as peripheral arterial disease in this summary) is common, affecting 3% to 7% of people in the general population and 20% of people over the age of 75.
1 It is associated with an increased risk of cardiovascular morbidity and mortality and severely limits people's functional capacity and quality of life. Peripheral arterial disease is often asymptomatic, but when it is symptomatic the most common presentation is intermittent claudication (pain in the legs, buttocks, or thighs brought on by walking and relieved by rest). Critical limb ischaemia is characterised by severely diminished circulation, ischaemic pain, ulceration, tissue loss, and/or gangrene. Owing to rapid changes in diagnostic methods, endovascular treatments, and vascular services, there is considerable uncertainty about the management of people with peripheral arterial disease, with management varying greatly across England and Wales. 2 This article summarises some of the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of peripheral arterial disease. 
Recommendations
NICE recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Secondary prevention of cardiovascular disease in people with peripheral arterial disease
• Offer all people with peripheral arterial disease information, advice, support, and treatment with respect to the secondary prevention of cardiovascular disease, in line with published NICE guidance on smoking cessation [4] [5] [6] [7] ; diet, weight management, and exercise [8] [9] [10] [11] ; lipid modification and statin therapy [12] [13] [14] ; the prevention, diagnosis, and management of diabetes [15] [16] [17] [18] [19] ; the prevention, diagnosis, and management of high blood pressure 20 ; and antiplatelet therapy. 21 -Record systolic blood pressure with an appropriately sized cuff in both arms and in the posterior tibial, dorsalis pedis, and, where possible, peroneal arteries.
-Take measurements manually using a Doppler probe of suitable frequency in preference to an automated system.
-Document the nature of the Doppler ultrasound signals in the foot arteries.
-Calculate the index in each leg by dividing the highest ankle pressure by the highest arm pressure.
[Based on experience and opinion of the GDG]

Imaging
• Offer duplex ultrasonography as first line imaging to all people for whom revascularisation is being considered.
• Offer contrast enhanced magnetic resonance angiography to people who need further imaging (after duplex ultrasonography) before considering revascularisation. If contrast enhanced magnetic resonance angiography is contraindicated or not tolerated, offer computed tomography angiography instead.
[ 
Overcoming barriers
A major problem in current practice is the failure to recognise the cardiovascular risk associated with a diagnosis of peripheral arterial disease and the importance of managing this risk through exercise, a healthy diet, smoking cessation, and management of diabetes, hypertension, and other related cardiovascular disease. The Guideline Development Group considered that the modification of risk factors for cardiovascular disease was a key priority for implementation as it was concerned that, although peripheral arterial disease is known to be a significant risk factor for cardiovascular morbidity and mortality, it may not be as widely recognised or as actively managed as other known risk factors. The guideline recommendation to offer supervised exercise programmes to all people with intermittent claudication is likely to lead to a major change to practice, but the availability and use of such programmes is variable and largely occurs within a secondary care setting. 3 Ideally, such programmes should be community based and easily accessible to patients. The set-up costs of new exercise programmes may be a barrier to implementation, but providers should note that the guideline recommendation of supervised exercise is backed by a detailed analysis showing this to be cost effective. Services could make use of or modify existing exercise programmes for cardiac or respiratory rehabilitation.
Further information on the guidance
Methods
The Guideline Development Group (GDG) followed the standard NICE methods in the development of this guideline (www.nice.org.uk/ aboutnice/howwework/developingniceclinicalguidelines/developing_nice_clinical_guidelines.jsp). 22 23 The group developed clinical questions; collected and appraised clinical evidence; and evaluated the cost effectiveness of proposed interventions through literature review and original economic modelling. The draft guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the group took all comments into consideration when producing the final version of the guideline. Quality ratings of the evidence were based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology (www.gradeworking group.org). These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study.
The GDG comprised three vascular surgeons (including the chairperson), two patient members, two interventional radiologists, a vascular scientist, a podiatrist, a general medicine physician, a pharmacist, a physiotherapist, a nurse, a general practitioner, and a pain consultant.
Future research
The GDG identified the following areas as priorities for research:
• What is the clinical and cost effectiveness of supervised exercise programmes compared with unsupervised exercise to treat people with intermittent claudication, taking into account the effects on long term outcomes and continuing levels of exercise?
• What is the effect of people's attitudes and beliefs about their peripheral arterial disease on the management and outcome of their condition?
• What is the clinical and cost effectiveness of a "bypass surgery first" strategy compared with an "angioplasty first" strategy to treat critical limb ischaemia caused by disease of the infrageniculate (below the knee) arteries?
• What is the clinical and cost effectiveness of selective stent placement compared with angioplasty plus primary stent placement to treat critical limb ischaemia caused by disease in the infrageniculate arteries?
• What is the clinical and cost effectiveness of chemical sympathectomy in comparison with other methods of pain control for managing critical limb ischaemic pain?
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